Join LGC scientists in the grudge match debate direct from Cambridge (UK) to decide the new king of quantitation.
Complexity of human diseases should promote the use of high-resolution mass spectrometry for routine untargeted analyses
In this editorial Bertrand Rochat (University of Lausanne, Switzerland) discusses the developments in the field of HRMS over the last 2 decades and his hopes for the future use of HRMS in routine untargeted analysis.
Both LBA and LC–MS have their place in drug discovery and development. What is the advantage of using them as complimentary tools?
Question 2: both LBA and LC–MS have their place in drug discovery and development. What is the advantage of using them as complimentary tools?
Question 1: could you briefly introduce yourself and your organization?
In this ‘Ask the Experts’ feature, we will be revisiting a previous Spotlight to investigate where we are now with hybrid LBA/LC–MS and what the future may hold for the technique.
In this editorial, Reiner Schulte (Cambridge Institute for Medical Research, UK) discusses the market of flow cytometry analyzers and cell sorters, highlighting some interesting developments in the field of flow cytometry.
Thermo Fisher Scientific (MA, USA) has announced the launch of their latest FTIR spectrometer, the Nicolet iS20, with new Optical Engineer technology, to improve the accuracy and delivery of analysis of complex samples for scientists.
Challenges and future predictions for oligonucleotide analysis: an interview with Hans-Peter Vornlocher
In this interview Hans-Peter Vornlocher, managing Director of Research at LGC Axolabs (Kulmbach, Germany), reflects on his career in the oligonucleotide field discussing the benefits and challenges of using oligonucleotides, his future predictions and what emerging technologies could aid analysis in the future.